Mucositis as a biological process: A new hypothesis for the development of chemotherapy-induced stomatotoxicity

Oral Oncology

Volumn 34, Issue 1, 1998, Pages 39-43

  Sonis, S T ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; CYTOKINE; CYTOTOXIC AGENT; DNA; FLUOROURACIL; MESSENGER RNA; METHOTREXATE;

ARTICLE; CANCER CHEMOTHERAPY; CYTOKINE RELEASE; HUMAN; HYPOTHESIS; IMMUNE DEFICIENCY; MOUTH FLORA; MOUTH MUCOSA; MOUTH ULCER; MUCOSA INFLAMMATION; PRIORITY JOURNAL; STOMATITIS;

ANTINEOPLASTIC AGENTS; CYTOKINES; HUMANS; MOUTH MUCOSA; OPPORTUNISTIC INFECTIONS; STOMATITIS;

EID: 0031944107     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(97)00053-5     Document Type: Article

References (51)

1. [1] Sonis S, Clark J. Prevention and management of oral mucositis induced by antineoplastic therapy. Oncology 1991;5:6-10.
2. [2] Sonis ST. Oral complications. In: Cancer Medicine, 4th Edition, JF Holland et al. Philadelphia: Willams & Wilkins, 1997. pp. 3255-3264.
3. [3] Schubert MM, Sullivan KMJ, Truelove EL. Head and neck complication of bone marrow transplantation. Developmental Oncology 1991;36:401-427.
4. [4] Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993;72:1612-1617.
5. [5] McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncology Nursing Forum 1993;20:1493-1502.
6. [6] Eting LS, Bodey GP, Keefe BH. Septicema and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clinical Infectious Diseases 1992;14:1201-1207.
7. [7] Reuscher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis of α-hemolytic streptococcal infections in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998. In press.
8. [8] Sonis ST, Costello KA. A database for mucositis induced by cancer chemotherapy. Oral Oncology, European Journal of Cancer 1995;31B:258-260.
9. [9] Borowski B, Benhamou E, Pivo JL, Laplanche A, Margainaud JP, Hayat M. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. Oral Oncology, European Journal of Cancer 1994;30B:93-97.
10. [10] Sonis S, Kunz A. Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. Oral Surgery, Oral Medicine, Oral Pathology 1988;65:19-22.
11. [11] Allison RR, Vongtama V, Vaughan J, Shin KH. Symptomatic acute mucositis can be minimized or prophylaxed by the combination of sucralfate and fluconazole. Cancer Investigations 1995;13:16-22.
12. [12] Dodd MJ, Larson PJ, Dibble SL, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncology Nursing Forum 1996;23:921-927.
13. [13] Gordon B, Spadinger A, Hodges E, Ruby E, Stanley R, Coccia P. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopotic stem-cell transplantation. Journal of Clinical Oncology 1995;13:1917-1922.
14. [14] Crawford J, Claspy J, Vincent M, Tomita D, Mazanet R. Effect of figrastim (r-metHug-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide CAE) (Meeting abstract). Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1994;13:A1523.
15. [15] Chi KH, Chen CH, Chan WK, et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil and leucovorin chemotherapy. Journal of Clinical Oncology 1994;13:2620-2628.
16. [16] Cartee L, Petros WP, Rosner GL, et al. Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine 1995;7:471-477.
17. [17] Wadleigh RG, Redman RS, Graham ML, Krasnow SH, Anderson A, Cohen MH. Vitamin E in the treatment of chemotherapy-induced mucositis. American Journal of Medicine 1992;92:481-484.
18. [18] Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis. A randomized double-blind study. Bone Marrow Transplantation 1996;17:809-812.
19. [19] Verdi CJ, Garewal HS, Koenig LM, Vaughn B, Burkhead T. A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodentics 1995;80:36-42.
20. [20] Osaki T, Ueta E, Yoneda K, Hirota J, Yamamoto T. Prophylaxis of oral mucositis associated with chemoradiotherapy for oral carcinoma by Azelastine hydrochloride (Azlastine) with other antioxidants. Head and Neck 1994;16:331-339.
21. [21] Labar B, Mrsic M, Pavletic Z, et al. Prostaglandin E2 for prophylxis of oral mucositis following BMT. Bone Marrow Transplantation 1993;11:379-382.
22. [22] Shenep JL, Kalwinsky DK, Hutson PR, et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. Pediatrics 1989;113:758-763.
23. [23] Jebb SA, Osborne RJ, Maughan TS, et al. 5-Fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. British Journal of Cancer 1994;70:732-735.
24. [24] Rocke L, Loprinzi CL, Lee JK, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993;72:2234-2238.
25. [25] Cascinu S, Fedeli A, Fedeli SL, Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Journal of Dermatologic Surgery and Oncology 1994;30B:234-236.
26. [26] Barasch A, Peterson DE, Tanzer JM, et al. Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1996;76:2550-2556.
27. [27] Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 1992;69:2469-2477.
28. [28] Donelly JP, Muus P, Schattenberg A, DeWitte T, Horrevorts A, DePauw BE. A scheme for daily monitoring of oral mucositis in allogenic BMT recipients. Bone Marrow Transplantation 1992;9:409-413.
29. [29] Tardieu C, Cowen D, Thirion X, Franquin JC. Quantitative scale of oral mucositis associated with autologous bone marrow transplantation. Journal of Dermatologic Surgery and Oncology 1995;32B:381-387.
30. [30] Verdi CJ. Cancer therapy and oral mucositis. An appraisal of drug prophylaxis. Drug Safety 1993;9:185-195.
31. [31] Mueller BA, Millheim ET, Farrington EA, Brusko C, Wiser TH. Mucositis management practices for hospitalized patients: national survey results. Journal of Pain and Symptom Management 1995;10:510-520.
32. [32] Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964-2968.
33. [33] Ferrara JL. Cytokines other than growth factors in bone marrow transplantation. Current Opinions in Oncology 1994;6:127-134.
34. [34] Krenger W, Ferrara JL. Graft-vs-host disease and the Th1/Th2 paradigm. Immunologic Research 1996;15:50-73.
35. [35] Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmerru B. Effect of total body irradiation, busulfan-cyclophosphamide or cyclophasphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-vs-host disease in H-2-incompatible transplanted ScID mice. Blood 1994;83:2360-2367.
36. [36] Aggarwal BB, Kohr WS, Hass PE. Human tumor necrosis factor. Production, purification and characterization. Journal of Biological Chemistry 1985;260:2345-2354.
37. [37] Ferrara JL, Abhyankar S, Gilliland DG. Cytokine stem of graft-versus-host disease: a critical effector role for interleukin-1. Transplantation Proceedings 1993;25:1216-1217.
38. [38] Sonis ST, Shklar G. Early tissue events in the development of experimental chemotherapy-induced mucositis. In preparation.
39. [39] Lockhart PB, Sonis ST. Alterations in the oral mucosa caused by chemotherapeutic agents. Journal of Dermatologic Surgery and Oncology 1981;7:1019-1025.
40. [40] Sonis AL, Sonis ST. Oral complications of cancer therapy in pediatric patients. Journal of Pedodontics 1979;3:12-16.
41. [41] Sonis ST, Costa JW Jr, Evitts SM, Lindquist LE, Nicolson M. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surgery, Oral Medicine, Oral Pathology 1992;74:749-755.
42. [42] Sonis ST, Lindquist L, VanVugt A, et al. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3. Cancer Research 1994;54:1135-1138.
43. [43] Sonis ST, VanVugt AG, O'Brien JP, et al. Transforming growth-factor β3-mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncology 1997;33:47-54.
44. [44] Cope PO, DeMeo M, Stiff P, et al. Prophylactic (anti-apoptotic) peptides delivered enterally to BMT patients inhibit chemotherapy induced mucositis (apoptotic cell death; ACD) in the esophageal/GI tract without moderating response rates: a preliminary evaluation (Meeting abstract). Proceedings of the Annual Meeting of the American Association of Cancer Research 1996;37:A1435.
45. [45] Kolbinson DA, Schubert MM, Flournoy N, Truelove EL. Early oral changes following bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1988;66(1):130-138.
46. [46] Sonis ST, Tracey C, Shklar G, Jenson J, Florine D. An animal model for mucositis induced by cancer chemotherapy. Oral Surgery, Oral Medicine, Oral Pathology 1990;69:437-443.
47. [47] Lockhart P, Sonis ST. Relationship of oral complications of peripheral blood leucocyte and platelet counts in patients receiving cancer chemotherapy. Oral Surgery, Oral Medicine, Oral Pathology 1979;48:21-28.
48. [48] Peterson DE. Pretreatment strategies for infection prevention in chemotherapy patients. NCI Monograph 1990;9:61-71.
49. [49] Gifford GE, Lohmann-Matthes ML. Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor by bacterial lipopolysaccharides. Journal of the National Cancer Institute 1987;78:121-124.
50. [50] Popovasilou AG. Transcription factors. New England Journal of Medicine 1995;332:45-47.
51. [51] Barnes PJJ, Karin M. Nuclear factor-κB - a pivotal transcription factor in chronic inflammatory diseases. New England Journal of Medicine 1997;336:1066-1071.